- Home
- MRC vs CVAC Comparison
MRC vs CVAC Comparison
Compare MRC & CVAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MRC
- CVAC
- Stock Information
- Founded
- MRC 1921
- CVAC 2000
- Country
- MRC United States
- CVAC Germany
- Employees
- MRC N/A
- CVAC N/A
- Industry
- MRC Industrial Machinery/Components
- CVAC Biotechnology: Pharmaceutical Preparations
- Sector
- MRC Industrials
- CVAC Health Care
- Exchange
- MRC Nasdaq
- CVAC Nasdaq
- Market Cap
- MRC 1.1B
- CVAC 1.2B
- IPO Year
- MRC 2012
- CVAC 2020
- Fundamental
- Price
- MRC $15.09
- CVAC $5.38
- Analyst Decision
- MRC Strong Buy
- CVAC Hold
- Analyst Count
- MRC 3
- CVAC 3
- Target Price
- MRC $16.00
- CVAC $6.83
- AVG Volume (30 Days)
- MRC 664.0K
- CVAC 636.4K
- Earning Date
- MRC 08-06-2025
- CVAC 08-15-2025
- Dividend Yield
- MRC N/A
- CVAC N/A
- EPS Growth
- MRC N/A
- CVAC N/A
- EPS
- MRC N/A
- CVAC 1.01
- Revenue
- MRC $2,945,000,000.00
- CVAC $599,540,810.00
- Revenue This Year
- MRC $5.81
- CVAC N/A
- Revenue Next Year
- MRC $5.43
- CVAC $24.04
- P/E Ratio
- MRC N/A
- CVAC $5.34
- Revenue Growth
- MRC N/A
- CVAC 675.15
- 52 Week Low
- MRC $9.23
- CVAC $2.37
- 52 Week High
- MRC $15.59
- CVAC $5.72
- Technical
- Relative Strength Index (RSI)
- MRC 60.32
- CVAC 46.15
- Support Level
- MRC $14.66
- CVAC $5.36
- Resistance Level
- MRC $15.08
- CVAC $5.48
- Average True Range (ATR)
- MRC 0.37
- CVAC 0.05
- MACD
- MRC 0.11
- CVAC -0.02
- Stochastic Oscillator
- MRC 81.01
- CVAC 11.11
About MRC MRC Global Inc.
MRC Global Inc distributes pipes, valves, fittings, and other infrastructure products and services to diversified gas utility, energy, and industrial end-markets. It provides supply chain solutions, technical product service and a digital platform for customers globally. It offers a range of PVF, oilfield supply, valve automation and modification, measurement, instrumentation, and other general and specialty products. Its geographical segments include the United States and International. It generates the majority of its revenue from the United States.
About CVAC CureVac N.V.
CureVac NV is a biopharmaceutical company headquartered in Germany that is developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA) that has the potential to improve the lives of people. CureVac had a collaboration with GSK to develop second-generation seasonal influenza and COVID-19 vaccines and an avian influenza vaccine. The company's other pipeline candidates include mRNA vaccines for oncology and molecular therapies spanning tumors, liver, and ocular diseases.